Weidan Ji

1.6k total citations
32 papers, 1.3k citations indexed

About

Weidan Ji is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Weidan Ji has authored 32 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Molecular Biology, 12 papers in Cancer Research and 10 papers in Oncology. Recurrent topics in Weidan Ji's work include MicroRNA in disease regulation (5 papers), Virus-based gene therapy research (4 papers) and Liver physiology and pathology (4 papers). Weidan Ji is often cited by papers focused on MicroRNA in disease regulation (5 papers), Virus-based gene therapy research (4 papers) and Liver physiology and pathology (4 papers). Weidan Ji collaborates with scholars based in China, United Kingdom and United States. Weidan Ji's co-authors include Changqing Su, Bin Sun, Yang Xu, Zhangxiao Peng, Quangen Gao, Haihua Qian, Yan Liu, Mengchao Wu, Xiaoya Li and Jianhui Fan and has published in prestigious journals such as PLoS ONE, Scientific Reports and Cancer Letters.

In The Last Decade

Weidan Ji

31 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Weidan Ji China 19 945 519 252 105 97 32 1.3k
Xiangxuan Zhao China 19 780 0.8× 386 0.7× 189 0.8× 62 0.6× 89 0.9× 39 1.2k
Yongxin Zou China 21 1.2k 1.2× 363 0.7× 269 1.1× 140 1.3× 82 0.8× 54 1.5k
Zhe Liu China 20 659 0.7× 328 0.6× 321 1.3× 54 0.5× 101 1.0× 53 1.2k
Zhongguang Luo China 17 670 0.7× 265 0.5× 277 1.1× 53 0.5× 215 2.2× 39 1.1k
Shiquan Liu China 21 742 0.8× 262 0.5× 244 1.0× 144 1.4× 189 1.9× 74 1.4k
Robert Wild United States 17 1.3k 1.3× 325 0.6× 263 1.0× 145 1.4× 49 0.5× 41 1.7k
Călin Ionescu Romania 14 814 0.9× 447 0.9× 265 1.1× 38 0.4× 70 0.7× 20 1.3k
Kin Chan Hong Kong 19 1.1k 1.2× 551 1.1× 277 1.1× 291 2.8× 108 1.1× 38 1.6k
Xing Guo China 21 974 1.0× 250 0.5× 257 1.0× 93 0.9× 175 1.8× 61 1.4k

Countries citing papers authored by Weidan Ji

Since Specialization
Citations

This map shows the geographic impact of Weidan Ji's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weidan Ji with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weidan Ji more than expected).

Fields of papers citing papers by Weidan Ji

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Weidan Ji. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weidan Ji. The network helps show where Weidan Ji may publish in the future.

Co-authorship network of co-authors of Weidan Ji

This figure shows the co-authorship network connecting the top 25 collaborators of Weidan Ji. A scholar is included among the top collaborators of Weidan Ji based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Weidan Ji. Weidan Ji is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Ji, Weidan, Wenchao Wang, Lei Chen, et al.. (2023). Circulating tumor cells participate in the formation of microvascular invasion and impact on clinical outcomes in hepatocellular carcinoma. Frontiers in Genetics. 14. 1265866–1265866. 6 indexed citations
3.
Xu, Yang, Jingui Duan, Weidan Ji, et al.. (2022). A novel matrine derivative, WM130, inhibits activation and movement of human hepatic stellate LX-2 cells by targeting cofilin 1. Cytotechnology. 74(6). 613–622. 5 indexed citations
4.
Yang, Feng, et al.. (2021). LncRNA CCAT1 Upregulates ATG5 to Enhance Autophagy and Promote Gastric Cancer Development by Absorbing miR-140-3p. Digestive Diseases and Sciences. 67(8). 3725–3741. 31 indexed citations
5.
Ji, Weidan, Zhangxiao Peng, Bin Sun, et al.. (2021). LpCat1 Promotes Malignant Transformation of Hepatocellular Carcinoma Cells by Directly Suppressing STAT1. Frontiers in Oncology. 11. 678714–678714. 12 indexed citations
6.
Peng, Zhangxiao, Yan–Xin Chang, Jianhui Fan, Weidan Ji, & Changqing Su. (2020). Phospholipase A2 superfamily in cancer. Cancer Letters. 497. 165–177. 81 indexed citations
7.
Yin, Haisen, Risheng Que, Chunying Liu, et al.. (2018). Survivin-targeted drug screening platform identifies a matrine derivative WM-127 as a potential therapeutics against hepatocellular carcinoma. Cancer Letters. 425. 54–64. 42 indexed citations
8.
Peng, Zhangxiao, Yan Wang, Jianhui Fan, et al.. (2017). Costunolide and dehydrocostuslactone combination treatment inhibit breast cancer by inducing cell cycle arrest and apoptosis through c-Myc/p53 and AKT/14-3-3 pathway. Scientific Reports. 7(1). 41254–41254. 69 indexed citations
9.
Li, Xiaoya, Yinghan Su, Bin Sun, et al.. (2016). An Artificially Designed Interfering lncRNA Expressed by Oncolytic Adenovirus Competitively Consumes OncomiRs to Exert Antitumor Efficacy in Hepatocellular Carcinoma. Molecular Cancer Therapeutics. 15(7). 1436–1451. 40 indexed citations
10.
Yi, Bin, Weidan Ji, Miaoyan Wei, et al.. (2016). Desulfation of cell surface HSPG is an effective strategy for the treatment of gallbladder carcinoma. Cancer Letters. 381(2). 349–358. 8 indexed citations
11.
12.
Liu, Kai, Minggao Guo, Xiaoli Lou, et al.. (2015). Hepatocyte nuclear factor 4α induces a tendency of differentiation and activation of rat hepatic stellate cells. World Journal of Gastroenterology. 21(19). 5856–5866. 7 indexed citations
13.
Liu, Yan, Yang Xu, Weidan Ji, et al.. (2015). Matrine derivative WM130 inhibits hepatocellular carcinoma by suppressing EGFR/ERK/MMP-2 and PTEN/AKT signaling pathways. Cancer Letters. 368(1). 126–134. 54 indexed citations
14.
Li, Zhigang, Xinxin Li, Chunguang Li, et al.. (2014). Transcription factor OCT4 promotes cell cycle progression by regulating CCND1 expression in esophageal carcinoma. Cancer Letters. 354(1). 77–86. 31 indexed citations
15.
Yan, Yan, Can Xu, Weidan Ji, et al.. (2013). MicroRNA-21 suppresses PTEN and hSulf-1 expression and promotes hepatocellular carcinoma progression through AKT/ERK pathways. Cancer Letters. 337(2). 226–236. 155 indexed citations
16.
Su, Yinghan, Xiaoya Li, Weidan Ji, et al.. (2013). Small molecule with big role: MicroRNAs in cancer metastatic microenvironments. Cancer Letters. 344(2). 147–156. 39 indexed citations
17.
Li, Chunguang, Zhigang Li, Tiejun Zhao, et al.. (2012). Clinicopathological and Prognostic Significance of Survivin Over-Expression in Patients with Esophageal Squamous Cell Carcinoma: A Meta-Analysis. PLoS ONE. 7(9). e44764–e44764. 28 indexed citations
18.
Li, Chun Guang, Yan Yan, Weidan Ji, et al.. (2012). OCT4 Positively Regulates Survivin Expression to Promote Cancer Cell Proliferation and Leads to Poor Prognosis in Esophageal Squamous Cell Carcinoma. PLoS ONE. 7(11). e49693–e49693. 65 indexed citations
19.
Hu, Liu, Xiaohui Fu, Weidan Ji, et al.. (2012). Human sulfatase‐1 inhibits the migration and proliferation of SMMC‐7721 hepatocellular carcinoma cells by downregulating the growth factor signaling. Hepatology Research. 43(5). 516–525. 14 indexed citations
20.
Ji, Weidan, Jiahe Yang, Lu Cao, et al.. (2011). hSulf-1 Gene Exhibits Anticancer Efficacy through Negatively Regulating VEGFR-2 Signaling in Human Cancers. PLoS ONE. 6(8). e23274–e23274. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xiangxuan Zhao Breakdown of academic impact, for papers by Yongxin Zou Breakdown of academic impact, for papers by Zhe Liu Breakdown of academic impact, for papers by Zhongguang Luo Breakdown of academic impact, for papers by Shiquan Liu Breakdown of academic impact, for papers by Robert Wild Breakdown of academic impact, for papers by Călin Ionescu Breakdown of academic impact, for papers by Kin Chan Breakdown of academic impact, for papers by Xing Guo
Rankless by CCL
2026